Non-Small-Cell Lung Cancer | Unmet Need | US/EU | 2016
Metastatic squamous-cell NSCLC is an incurable disease associated with a dismal 5 year OS of <5%; treatments delivering improvements to survival are therefore a key treatment goal in this disease. Despite recent approvals of Portrazza, Opdivo and Keytruda for metastatic squamous-cell NSCLC, surveyed oncologists highlight that novel therapies with improved clinical efficacy are still an area of high unmet need. This report investigates key drivers of prescribing in squamous-cell NSCLC, and identifies key areas of unmet need in the indication.
Related Market Assessment Reports
Report
Alzheimer’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alzheimer’s Disease (US)
The treatment of early Alzheimer’s disease (AD) is being transformed by the launches of Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s donanemab (Kisunla), and additional disease-…
Report
Parkinson’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Parkinson’s Disease (US)
Parkinson’s disease (PD) is a progressive neurodegenerative condition that is treated chronically with prescription therapies from an array of mechanistically distinct drug classes, including…
Report
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric ADHD (US)
ADHD is a common pediatric neurodevelopmental disorder, with diagnosis rates supported by increased awareness and routine screening; however, symptoms often persist into adulthood. Longacting…
Report
Obesity – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
